The biotechnology developer was backed by Zhongji Holdings in the round and will use the capital to complete product development on its temperature management device.
US-based biotechnology developer Qool Therapeutics closed an $8m series A-1 round yesterday featuring real estate and property management group Zhongji Holdings.
Join Medical Technology, BrilliMedical International, BioPacific Investors, Western Technology Investment, FundRx and Tamcap contributed to the round.
The company also received an award from Defense Innovation Unit Experimental, a US Department of Defense commercial technology accelerator.
Qool is developing a device for targeted temperature management and exercise recovery. The technology could be used to cool a patient’s organs and…